Core Insights - Merck is nearing an agreement to acquire biotech company Cidara Therapeutics, with the deal likely valuing Cidara above its current market cap of $3.3 billion, potentially announced as early as this Friday [1] - The acquisition is driven by Cidara's promising drug CD388, which recently received "Breakthrough Therapy" designation from the FDA, highlighting its clinical value in preventing influenza in high-risk populations [2] Company Summary - Merck is competing with another pharmaceutical company for the acquisition of Cidara, with the final decision favoring Merck's proposal [1] - The specific price of the acquisition has not been disclosed, but it is expected to involve a combination of cash and milestone payments linked to clinical trial achievements of Cidara's drugs [1] - Cidara has not commented on the acquisition rumors, and Merck has not responded to inquiries regarding the matter [1] Industry Summary - The "Breakthrough Therapy" designation by the FDA is designed to expedite the development and review of drugs for serious diseases or unmet medical needs, underscoring the significance of CD388 in the influenza prevention market [2] - If the acquisition is successful, it will enhance Merck's pipeline in the anti-infective space, while Cidara's innovative drug development capabilities will benefit from Merck's resources, potentially leading to faster market introduction of new treatment options for influenza prevention [2]

Merck is closing in on a deal to buy Cidara Therapeutics in a deal valuing the biotechnology company at a premium to its $3.3 billion market capitalization, the Financial Times reported on Thursday. ...

Summary of Cidara Therapeutics FY Conference Call Company Overview - Cidara Therapeutics is an 11-year-old biotechnology company focused on developing a universal influenza preventative, CD388, based on its Cloudbreak platform [4][5][6] Core Points and Arguments - **Clinical Development**: CD388 has progressed through preclinical testing and multiple clinical phases, with a successful phase 2b study demonstrating a 76.1% efficacy rate against influenza [7][10] - **FDA Interaction**: The FDA has recommended expanding the phase 3 trial to include high-risk populations, specifically those over 65 years old, in addition to immunocompromised individuals [10][12] - **Phase 3 Study Design**: The ongoing phase 3 study involves 6,000 participants testing the 450 mg dose of CD388 versus placebo, with an interim analysis expected by March 2026 [12][13] - **Efficacy Expectations**: The study is designed to be 90% powered to detect a 60% efficacy rate, with the potential for stronger results if the flu season is severe [12][13] - **Real-World Testing**: The phase 3 study allows for vaccination among participants to assess CD388's effectiveness in both vaccinated and unvaccinated individuals [19][20] Market Opportunity - **Target Population**: Cidara estimates over 100 million patients could be eligible for CD388, including 50 million with moderate to severe comorbidities and another 100 million at increased risk according to CDC guidelines [25][26] - **Pricing and Access**: Ongoing market research is being conducted to understand pricing and access opportunities, with updates expected at the upcoming analyst day [26][27] Manufacturing and Supply Chain - **Manufacturing Plans**: Cidara is preparing to have millions of doses ready at launch, with a focus on establishing a domestic supply chain through a contract with BARDA for onshore manufacturing [29][33] Additional Insights - **Safety and Efficacy**: CD388 is characterized as a long-acting antiviral, distinct from vaccines, and is expected to maintain efficacy throughout the flu season [7][20] - **Regulatory Support**: The FDA has indicated that the phase 2b study could support the registration package, enhancing the potential for a broad label upon approval [23] This summary encapsulates the key points discussed during the Cidara Therapeutics FY Conference Call, highlighting the company's strategic direction, clinical advancements, market potential, and operational plans.

Financial Data and Key Metrics Changes - Cidara Therapeutics reported a strong financial position with approximately $476 million in cash as of September 30, 2025, fully funding its phase three development program [12] - A $45 million milestone payment was triggered by the initiation of the phase three trial, which will be recorded in Q3 but paid in Q4 [6] Business Line Data and Key Metrics Changes - The lead candidate, CD388, has advanced into phase three development, with the trial starting six months earlier than planned [4][5] - The phase two B Navigate Study demonstrated a 76.1% protective efficacy with a single 450 milligram dose of CD388, reinforcing its potential as a long-acting antiviral for influenza prophylaxis [9][10] Market Data and Key Metrics Changes - The enrollment for the phase three trial has expanded to include healthy adults over 65, increasing the potential patient population from 50 million to over 100 million in the U.S. [7][8] - The study is over 50% enrolled and is on track to achieve target enrollment by December [9] Company Strategy and Development Direction - Cidara's strategy focuses on the development of CD388 as a non-vaccine preventative for influenza, leveraging its proprietary Cloudbreak platform [5] - The company received breakthrough therapy designation from the FDA, which will enhance access to regulatory guidance and potentially accelerate development timelines [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical data supporting CD388 and its differentiated profile compared to existing vaccines and antivirals [10] - The company plans to host a virtual R&D day on December 15, 2025, to provide updates on the CD388 program and market research insights [12] Other Important Information - Cidara received a $339 million award from BARDA to support expanded manufacturing and clinical development of CD388, with a base period valued at $58 million over the first 24 months [11][12] - The company is working on establishing a full U.S. commercial supply chain to meet potential market demand [36] Q&A Session Summary Question: How will the external statistician decide on additional patient enrollment at the interim analysis? - The external statistician will assess data at a pre-specified time point to determine if the powering assumptions were met, without sharing specific data with Cidara [15][16] Question: Will efficacy data be available at the interim analysis? - No efficacy data will be shared at the interim analysis; only whether the powering assumptions have been met will be communicated [19][21] Question: How does the inclusion of healthy individuals over 65 impact vaccine rates and event rates? - The addition of this population is expected to expedite enrollment and maintain similar placebo attack rates, with a higher background vaccination rate anticipated [46][48] Question: What is the scale of manufacturing at WuXi and what are the rate-limiting factors for BLA filing? - WuXi is expected to produce around 5 million doses per year, with rate-limiting factors related to qualification requirements for BLA readiness [39][40] Question: What is the potential for CD388 in pandemic settings? - Cidara is conducting studies on CD388's efficacy against pandemic strains, with promising results against H5N1, and plans to continue research on other strains [56][57]

Clinical Development - The company has completed two Phase 1 studies and one Phase 2a study of CD388, with positive topline results announced for the Phase 2b NAVIGATE study involving 5,041 subjects, demonstrating a prevention efficacy of 76.1% for the 450 mg dose group [210][211]. - The NAVIGATE study met its primary endpoint, showing statistically significant prevention efficacy across all dose groups, with no unexpected adverse events reported [210][217]. - The company plans to initiate a Phase 1 vaccine interaction study and a Phase 2 repeat dose study of CD388 in mid-November 2025 [209]. - The ANCHOR study has a target enrollment of 6,000 participants, with over 50% enrolled as of November 2025, and expected completion by December 2025 [222]. - The interim analysis of the ANCHOR study is scheduled for the first quarter of 2026 to assess trial size and determine the need for additional enrollment [222]. Regulatory Designations - The FDA granted Fast Track designation to CD388 in June 2023 and Breakthrough Therapy designation in October 2025, aimed at expediting the development and review process for the drug [201]. Financial Performance - As of September 30, 2025, the company reported an accumulated deficit of $743.7 million and expects to continue incurring net losses [226]. - The company had cash, cash equivalents, restricted cash, and available-for-sale investments totaling $476.5 million as of September 30, 2025, sufficient to fund operations through the Phase 3 development program [227]. - Research and development expenses for the three months ended September 30, 2025, were $35.5 million, an increase of $23.1 million compared to the same period in 2024 [246]. - Acquired in-process research and development expenses were $45.0 million for the three months ended September 30, 2025, related to a milestone under the Janssen License Agreement [247]. - Total R&D expenses for the nine months ended September 30, 2025, were $84.9 million, up from $25.0 million in 2024, mainly due to the NAVIGATE study and ANCHOR study preparations [256]. Funding and Agreements - The company raised $240 million in gross proceeds from a private placement in April 2024, with $85 million allocated for the upfront payment under the Janssen License Agreement, and additional funding secured from subsequent placements and a public offering [202]. - A contract with BARDA was established in September 2025, providing potential payments of up to $339.2 million, including base period funding of approximately $58.1 million over 24 months [205]. - The BARDA Agreement includes an estimated funding of $58.1 million over 24 months for CD388 manufacturing and clinical trials, with potential additional funding of up to $281.1 million [223]. Stock and Market Performance - The company has 42,017,928 shares of common stock equivalents outstanding as of September 30, 2025 [225]. - The stock market for pharmaceutical and biotechnology companies has experienced significant volatility, impacting market prices unrelated to operating performance [224]. - The company completed a Public Offering in June 2025, raising approximately $402.5 million from the sale of 9,147,727 shares at $44.00 per share [267]. Cash Flow and Operating Activities - Net cash used in operating activities for the nine months ended September 30, 2024 was $117.5 million, adjusted for $5.2 million of non-cash operating activities and $34.8 million of changes in operating assets and liabilities [275]. - The primary use of cash for all periods presented was to fund R&D activities, which are expected to continue to increase in the foreseeable future [276]. - Net cash provided by financing activities during the nine months ended September 30, 2025 included net proceeds of $376.9 million from the sale of 9,147,727 shares of common stock at $44.00 per share [278]. - The absence of cash outflows from discontinued operations is expected to reduce operating cash outflows from continuing operations [281]. - The company plans to fund losses from operations through cash, cash equivalents, restricted cash, and available-for-sale investments, as well as future equity offerings and debt financings [282].

Exhibit 99.1 • Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeutic • Enrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the Northern Hemisphere by December 2025; Phase 3 initiation triggered $45.0 million milestone payment to Janssen • BARDA award to support expanded manufacturing and clinical development of CD388 • FDA granted Breakthrough Therapy designation to CD388 • Conference call and webcast ...

Core Insights - Cidara Therapeutics reported financial results for Q3 2025 and provided updates on its CD388 program, which is in Phase 3 development as a potential universal preventative for influenza [1][2][4] Financial Performance - As of September 30, 2025, the company had cash, cash equivalents, restricted cash, and available-for-sale investments totaling $476.5 million, a significant increase from $196.2 million as of December 31, 2024 [7][17] - Collaboration revenue was zero for Q3 2025 and the nine months ended September 30, 2025, compared to $1.3 million for the same periods in 2024 [7] - The net loss for Q3 2025 was $83.2 million, compared to a net loss of $16.0 million for Q3 2024 [8][15] CD388 Development Updates - The Phase 3 ANCHOR study for CD388 is over 50% enrolled, with a target of 6,000 participants expected to be reached by December 2025 [2][5] - The study population has been expanded to include healthy adults over 65 years old, increasing the potential eligible population from approximately 50 million to over 100 million in the U.S. [5] - The FDA granted Breakthrough Therapy designation to CD388, which is intended to expedite the review process for therapies that show substantial improvement over existing options [5][11] Corporate Highlights - Cidara received a BARDA award valued at up to $339.2 million to support the manufacturing and clinical development of CD388 [4][5] - The company initiated the ANCHOR study in September 2025, which includes an interim analysis planned for Q1 2026 [5][6] - Presentations highlighting CD388 were made at various medical conferences, showcasing positive results from the Phase 2b NAVIGATE study [6]

Core Insights - Cidara Therapeutics, Inc. is participating in two upcoming investor conferences in November 2025, including the Guggenheim 2 Annual Healthcare Innovation Conference and the Jefferies London Healthcare Conference [1][2] Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) therapeutics, with a focus on targeted small molecules or peptides linked to a human antibody fragment [3] - The lead DFC candidate, CD388, is designed for long-acting antiviral treatment aimed at universal prevention of seasonal and pandemic influenza with a single dose by inhibiting viral proliferation [3] - CD388 received Fast Track Designation from the FDA in June 2023 and has shown positive top-line results from its Phase 2b NAVIGATE trial in June 2025, with a Phase 3 ANCHOR trial initiated in September 2025 [3]

Core Viewpoint - H.C. Wainwright maintains a "Buy" rating for Cidara Therapeutics, Inc. following promising data on its influenza preventative candidate CD388, despite a slight decrease in stock price [1][5]. Company Overview - Cidara Therapeutics is a biotechnology company focused on developing innovative anti-infectives, particularly for influenza prevention [1]. - The company has a market capitalization of approximately $2.47 billion, indicating a strong position within the biotechnology sector [4][5]. Recent Developments - Cidara presented promising data on CD388 at the 10th European Scientific Working Group on Influenza Conference, highlighting its translational efficacy and supporting the ongoing Phase 3 ANCHOR trial [2][5]. - The Phase 2b NAVIGATE study results have bridged preclinical findings with recent clinical outcomes, reinforcing the potential of CD388 [2]. Stock Performance - Despite the positive developments, CDTX's stock price has decreased by 2.03%, currently priced at $97.31, with fluctuations between $97.15 and $99.25 on the day [3]. - Over the past year, CDTX has experienced significant volatility, with a high of $121.21 and a low of $11.12 [3]. - The trading volume for the day stands at 161,126 shares, suggesting moderate investor interest [4].

Core Insights - Cidara Therapeutics, Inc. will report its Q3 2025 financial results and operational highlights on November 6, 2025, after U.S. market close [1] - A conference call and webcast will be held at 5:00 PM Eastern Time to discuss the results and business updates [2] Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies [3] - The lead DFC candidate, CD388, is designed for universal prevention of seasonal and pandemic influenza with a single dose by inhibiting viral proliferation [3] - CD388 received Fast Track Designation from the FDA in June 2023 and has shown positive results in the Phase 2b NAVIGATE trial in June 2025, with a Phase 3 ANCHOR trial initiated in September 2025 [3]